Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
Developing a new aids chemoimmunotherapy (CI) (Meeting abstract).
Proc Annu Meet Am Assoc Cancer Res; 14:A837 1995. Unique Identifier : AIDSLINE ICDB/95613989 Hollinshead A; George Washington Univ. Medical Center, Washington DC
Abstract:
In early studies, we reported that certain purine and pyrimidine analogues and sulfur-containing compounds affect host cells in such a way as to inhibit or prevent virus entry or multiplication, some by competitive inhibition. Four showed safety and gave protection in mice infected with poliovirus or influenza virus, but a later development of resistance to each of the 3 nucleic acid base analogues was demonstrated. The 4th compound, thiophenoyl urea (TUR), was tested against HIV in vitro and showed a good inhibitory ratio. TUR was administered orally to 2 late stage cancer patients, mixed as 0.03 to 0.04% of a semi-liquid diet food, TID for 3 wk, with no side effects. Using methods tested for other diseases, early nonstructural HIV components were obtained from separated cell and nuclear membranes of HIV infected cells harvested 4 hr after infection and stored less than 1 week at -75 C. (We reported that early viral components which do not become a part of the structure of the mature virus may disappear if frozen too long.) Membranes were gently sonicated over ice in neutral PBS, centrifuged and the supernate separated on Sephadex G-200, and 2nd peak eluates, which contained nonvirion antigens (NVA) were concentrated. In a specific lymphocyte (from HIV patient) stimulation assay, a titration effect was observed. Emulsification of 150 ug protein/0.1 ml NVA with 0.1 ml incomplete Freund's adjuvant was used as vaccine, administered slowly ID monthly x3 to an HIV positive patient. Cell-mediated immune responses but no toxicity reactions were observed during the course of 6 mo after the 1st immunization. At 6 mo the patient became HIV seronegative. CI: Two AIDS patients received TUR for 3 weeks, followed by NVA vaccine monthly x3. Both were still sick at 3 mo but at 6-9 mo showed improvement. Both are alive and free of disease 2 yr post-CI, suggesting other studies.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Animal *Antiviral Agents/*THERAPEUTIC USE Combined Modality Therapy Human HIV/DRUG EFFECTS Immunity, Cellular *Immunotherapy Lymphocyte Transformation Lymphoma, AIDS-Related/PATHOLOGY/*THERAPY Mice Neoplasm Staging Phenylthiourea/PHARMACOLOGY/*THERAPEUTIC USE ABSTRACT 951230
M95C3217
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
